HALIFAX,
Jan. 24, 2014 /CNW/ - MedMira
Inc., (MedMira) (TSXV: MIR), a developer of rapid testing
technologies and solutions, reported that the Company's Board of
Directors was elected at its 2014 Annual General Meeting of
Shareholders held earlier today in Halifax, N.S. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto, Mr. Markus Meile and Dr. Michael Sidler were re-elected as directors of
MedMira.
Shareholders also approved the appointment of
Deloitte LLP as the Company's auditors.
About MedMira
MedMira is a leading developer and manufacturer
of rapid testing technology and solutions. The Company's tests
provide hospitals, labs, clinics and individuals with reliable,
rapid diagnosis for diseases such as HIV and hepatitis C in just
three minutes. The Company's tests are sold under the Reveal®,
Multiplo™ and Miriad brands in global markets. MedMira's patented
rapid flow-through HIV test is the only one in the world to achieve
regulatory approvals in Canada,
the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
